Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Adam Rosenthal, Nathan Petty, MS, Maurizio Zangari, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MDPhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 5395.

https://doi.org/10.1182/blood.V126.23.5395.5395

Published: 2015

Journal Articles

Spectrum of Cerebrovascular Disease in Multiple Myeloma Patients Undergoing Chemotherapy

Archana Hinduja, MD, Kaustubh Limaye, MD, Rahul Ravilla, MD, Appalanaidu Sasapu, MD MS, Xenofon Papanikolaou, MD, Sarah Waheed, MD

Blood (2015) 126 (23): 5498.

https://doi.org/10.1182/blood.V126.23.5498.5498

Published: 2015

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma

Xenofon Papanikolaou, MD, Caleb K. Stein, MS, Ricky D Edmondson, PhD, Veronica Macleod, Ruslana Tytarenko, Bart Barlogie, MD PhD, Joshua Epstein, DSc, Christoph Heuck, MD

Blood (2015) 126 (23): 499.

https://doi.org/10.1182/blood.V126.23.499.499

Published: 2015

Journal Articles

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Rashid Z Khan, MD, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, MB, MRCP, MD FRCPath, Christoph Heuck, MD, Susan B. Panozzo, BS, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Carolina Schinke, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2128.

https://doi.org/10.1182/blood.V124.21.2128.2128

Published: 2014

Journal Articles

PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients

Yogesh Jethava, MB, MRCP, MD FRCPath, Rachel Hunter-Merrill, Gareth J Morgan, MD PhD, Rashid Z Khan, MD, Aasiya Matin, MD, Christoph Heuck, MD, Maurizio Zangari, MD, Xenofon Papanikolaou, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3407.

https://doi.org/10.1182/blood.V124.21.3407.3407

Published: 2014

Journal Articles

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Maurizio Zangari, MD, Caleb K Stein, MS, Shmuel Yaccoby, PhD, Donghoon Yoon, PhD, Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Donald Johann, MD MS, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3409.

https://doi.org/10.1182/blood.V124.21.3409.3409

Published: 2014

Journal Articles

Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience

Xenofon Papanikolaou, MD, Sarah Waheed, MD, Bart Barlogie, MD PhD, Daisy V. Alapat, MD, Donghoon Yoon, PhD, Manoj Kumar, MD, Aasiya Matin, MD, Hongyun Zhu, MD, Cerisse Harcourt, APN, Maurizio Zangari, MD

Blood (2014) 124 (21): 2999.

https://doi.org/10.1182/blood.V124.21.2999.2999

Published: 2014

Journal Articles

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Rashid Z Khan, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Xenofon Papanikolaou, MD, Caleb K Stein, MS, Adam Rosenthal, Christoph Heuck, MD, Frits van Rhee, MD PhD, Jameel Muzaffar, MD, Maurizio Zangari, MD, Clyde Bailey, Phillip Farmer, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 5770.

https://doi.org/10.1182/blood.V124.21.5770.5770

Published: 2014

Journal Articles

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Rashid Z Khan, MD, Christoph Heuck, MD, Adam Rosenthal, Caleb K Stein, MS, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Xenofon Papanikolaou, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Frits Van Rhee, Madhav V. Dhodapkar, MD, Gareth J Morgan, MD PhD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2078.

https://doi.org/10.1182/blood.V124.21.2078.2078

Published: 2014

Journal Articles

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Xenofon Papanikolaou, MD, Adam Rosenthal, Rashid Z Khan, MD, Joshua Epstein, DSc, Christoph Heuck, MD, Madhav V. Dhodapkar, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Omar Atiq, MD, Sarah Waheed, MD, Faith Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2079.

https://doi.org/10.1182/blood.V124.21.2079.2079

Published: 2014

Journal Articles

Characteristics and Prognosis Of IgM Multiple Myeloma

Shebli Atrash, MD, Qing Zhang, PhD, Xenofon Papanikolaou, MD, Christoph Heuck, MD, Aziz Bakhous, M.D., Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1881.

https://doi.org/10.1182/blood.V122.21.1881.1881

Published: 2013

Journal Articles

The Antimalarial Agent Artesunate Exerts Its Antimyeloma Activity By Affecting The Mitochondria and The Reactive Oxygen Status Of The Myeloma Cells and Its Efficacy Depends On Intracellular Bivalent Iron Levels

Xenofon Papanikolaou, MD, Sarah K. Johnson, PhD, Tarun K. Garg, PhD, Erming Tian, PhD, Ruslana Tytarenko, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, Christoph Heuck, MD

Blood (2013) 122 (21): 4444.

https://doi.org/10.1182/blood.V122.21.4444.4444

Published: 2013

Journal Articles

Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival

Xenofon Papanikolaou, MD, Qing Zhang, PhD, Christoph Heuck, MD, Sarah Waheed, MD, Shebli Atrash, MD, Zeba N Singh, MD, Daisy V. Alapat, MD, Frits van Rhee, MD, PhD, Shweta S. Chavan, PhD, Joshua Epstein, DSc, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1911.

https://doi.org/10.1182/blood.V122.21.1911.1911

Published: 2013

Journal Articles

The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis

Xenofon Papanikolaou, MD, Ruslana Tytarenko, Tarun K. Garg, PhD, Sarah K. Johnson, PhD, Erming Tian, Senu Apewokin, MD, Bart Barlogie, MD, Joshua Epstein, DSc, Christoph Heuck, MD

Blood (2012) 120 (21): 4015.

https://doi.org/10.1182/blood.V120.21.4015.4015

Published: 2012

Journal Articles

DNA Flow Cytometry and Metaphase Cytogenetics Can Predict Progression of Asymptomatic Monoclonal Gammopathies (AMG) to Symptomatic Multiple Myeloma (MM).

Xenofon Papanikolaou, MD, Sarah Waheed, MD, Madhav V. Dhodapkar, MD, Saad Z Usmani, MD FACP, Christoph Heuck, MD, Frits van Rhee, MD, PhD, Joshua Epstein, DSc, Bart Barlogie, MD

Blood (2012) 120 (21): 2915.

https://doi.org/10.1182/blood.V120.21.2915.2915

Published: 2012

Journal Articles

Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘'era” of Novel Therapies in Multiple Myeloma (MM).

Xenofon Papanikolaou, MD, Jackie Szymonifka, Susann Szmania, Katie Stone, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Christoph Heuck, MD, Frits van Rhee, MD, PhD, Joshua Epstein, DSc, Antje Hoering, Bart Barlogie, MD

Blood (2012) 120 (21): 2918.

https://doi.org/10.1182/blood.V120.21.2918.2918

Published: 2012

Journal Articles

Hematopoietic Progenitor Cell (HPC) Collection Is Feasible in Previously Transplanted Multiple Myeloma Patients and Plerixafor Improves Collection

Xenofon Papanikolaou, MD, Lisa Tyler, Bart Barlogie, MD, PhD, Michele Cottler-Fox, MD

Blood (2012) 120 (21): 4127.

https://doi.org/10.1182/blood.V120.21.4127.4127

Published: 2012

NARROW

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Spectrum of Cerebrovascular Disease in Multiple Myeloma Patients Undergoing Chemotherapy

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Characteristics and Prognosis Of IgM Multiple Myeloma

The Antimalarial Agent Artesunate Exerts Its Antimyeloma Activity By Affecting The Mitochondria and The Reactive Oxygen Status Of The Myeloma Cells and Its Efficacy Depends On Intracellular Bivalent Iron Levels

Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival

The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis

DNA Flow Cytometry and Metaphase Cytogenetics Can Predict Progression of Asymptomatic Monoclonal Gammopathies (AMG) to Symptomatic Multiple Myeloma (MM).

Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘'era” of Novel Therapies in Multiple Myeloma (MM).

Hematopoietic Progenitor Cell (HPC) Collection Is Feasible in Previously Transplanted Multiple Myeloma Patients and Plerixafor Improves Collection

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only